A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder

Trial Profile

A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder

Completed
Phase of Trial: Phase II/III

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Dasotraline (Primary)
  • Indications Binge-Eating Disorder
  • Focus Therapeutic Use
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 23 May 2017 Results published in the Sunovion Pharmaceuticals Media Release
    • 13 Jan 2017 According to a Sunovion Pharmaceuticals Media Release, full results of study SEP360-221 and study SEP360-301 are being analyzed and will be presented at upcoming scientific meetings.
    • 13 Jan 2017 Primary endpoint has been met. (Change from baseline in number of binge days (defined as days during which at least 1 binge episode occurs) per week to Week 12), as reported in a Sunovion Pharmaceuticals Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top